- Stocks
- Pharma & Healthcare
- Novelix Pharma
Novelix Pharma share price
NSE: NOVELIXPharma & HealthcareMedical Distribution
Novelix Pharma at a glance
With a market capitalisation of ₹181 Cr, it ranks 2337th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.
Its return on equity was −24.3% in FY22. In Q2 FY23, the quarter ended 30 Sep 2022, revenue was ₹1 Cr (−49.6% year on year) and net profit −₹0 Cr (−140.0%), on a consolidated basis. Promoters held 54.29% of the company as of 17 Jul 2026.
Key numbers
- Market cap
- ₹181 CrRank 2337 on NSE
- Price to book
- 0.97×FY22
- EPS (TTM)
- −₹2.74to Q2 FY23
- ROE
- −24.3%FY22
- ROCE
- −27.2%FY22
- Debt to equity
- 0.02FY22
- Net profit margin
- −24.6%FY22
- Book value / share
- ₹9.48FY22
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Novelix Pharma quarterly results
| Quarter | Q3 FY21 | Q4 FY21 | Q1 FY22 | Q2 FY22 | Q3 FY22 | Q4 FY22 | Q1 FY23 | Q2 FY23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Revenue YoY | −13.1% | −5.6% | +112.2% | −0.8% | −49.3% | −72.5% | −68.7% | −49.6% |
| Net profit | −₹0 Cr | −₹3 Cr | −₹0 Cr | ₹0 Cr | −₹1 Cr | −₹2 Cr | −₹0 Cr | −₹0 Cr |
| Net profit YoY | — | −11,000.0% | — | — | — | — | — | −140.0% |
| Net margin | −10.5% | −130.3% | −3.2% | 14.2% | −63.1% | −231.9% | −8.1% | −11.3% |
| EPS | −₹0.26 | −₹4.05 | −₹0.18 | ₹0.39 | −₹0.77 | −₹1.67 | −₹0.11 | −₹0.19 |
Novelix Pharma financials
| Item | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 |
|---|---|---|---|---|---|---|
| Revenue | ₹9 Cr | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹9 Cr |
| Operating profit | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹4 Cr | −₹2 Cr |
| Net profit | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹4 Cr | −₹2 Cr |
| EPS (₹) | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | −₹5.00 | −₹2.00 |
| Cash from operations | −₹2 Cr | ₹0 Cr | −₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr |
| Total debt | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹12 Cr | ₹11 Cr | ₹11 Cr | ₹11 Cr | ₹7 Cr | ₹7 Cr |
Novelix Pharma shareholding pattern
| Holder | 12 Feb 2026 | 30 Mar 2026 | 31 Mar 2026 | 7 Jun 2026 | 30 Jun 2026 | 17 Jul 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.51% | 49.43% | 49.43% | 50.57% | 50.57% | 54.29% |
| Non-institutions | 53.49% | 50.57% | 50.57% | 49.43% | 49.43% | 45.71% |
Novelix Pharma vs peers
The listed Pharma & Healthcare companies nearest to Novelix Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| OXYGENTAPHOXYGENTA PHARMA | — | — | — | ₹185 Cr | — | — |
| ANLAccretion Nutra | — | — | — | ₹184 Cr | — | — |
| EARKARTEarkart | — | — | — | ₹182 Cr | — | — |
| NOVELIXNovelix Pharma | — | — | — | ₹181 Cr | — | — |
| MEDICOMedico Remedies | ₹21.68 | −2.03% | −56.8% | ₹180 Cr | 13.7 | — |
| TAKETake Solutions | ₹11.96 | −5.23% | −25.9% | ₹177 Cr | 41.2 | — |
| BALPHARMABal Pharma | ₹109.58 | −2.16% | +28.9% | ₹174 Cr | 27.7 | — |
Ask anything about Novelix Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against NOVELIX's own history. Try: “Why has NOVELIX moved over the last three months?” · “Backtest a 50-day moving-average crossover on NOVELIX over five years” · “Compare NOVELIX with OXYGENTAPH on margins and valuation”
Frequently asked questions about Novelix Pharma
What is the market cap of Novelix Pharma?
Novelix Pharma's market capitalisation is ₹181 Cr (₹181 Cr) at the 19 Oct 2026 close, ranking 2337th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Novelix Pharma?
Return on equity was −24.3% in FY22 and return on capital employed was −27.2% in FY22 (consolidated figures).
Is Novelix Pharma a debt-free company?
Novelix Pharma is close to debt-free: its debt-to-equity ratio was 0.02 in FY22.
What were Novelix Pharma's latest quarterly results?
For Q2 FY23 (quarter ended 30 Sep 2022), Novelix Pharma reported revenue of ₹1 Cr, −49.6% year on year, and net profit of −₹0 Cr, −140.0% year on year.
What is the shareholding pattern of Novelix Pharma?
As of 17 Jul 2026: promoters 54.29%, non-institutions 45.71%.
Who are Novelix Pharma's competitors?
The listed Pharma & Healthcare companies closest to Novelix Pharma by market cap are OXYGENTA PHARMA, Accretion Nutra, Earkart, Medico Remedies, Take Solutions and Bal Pharma.
Is Novelix Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Novelix Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NOVELIX against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text